Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral HPBCD in adults with stable coronary artery disease
ACTRN12622001377729Phase 2Completed
- Sponsor
- Thermo Fisher Scientific
- Start
- Dec 2022
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Trappsol Cyclo in coronary arteriosclerosis, sponsored by Thermo Fisher Scientific. Primary endpoint: Safety and tolerability of multiple oral doses of HPBCD. Started Dec 2022; status: completed.
02
Drugs
Trappsol Cyclo
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on ACTRN12622001377729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622001377729.